FDA to review Blue Earth's Axumin for brain cancer

The U.S. Food and Drug Administration (FDA) has accepted molecular imaging...Read more on AuntMinnie.comRelated Reading: Blue Earth study reports Axumin can aid glioma diagnosis Blue Earth promotes results for PET/CT agent Blue Earth expands PSMA-PET/CT imaging portfolio Blue Earth touts addition of Axumin to NCCN guidelines Blue Earth highlights Axumin clinical results at ASTRO
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news

Related Links:

Abstract Recent reports describe how genome-wide transcriptional analysis of cancer tissues can be exploited to identify molecular signatures of immune infiltration in cancer. We hypothesize that immune infiltration in cancer may also be defined by changes in certain epigenetic signatures. In this context, a primary objective is to identify site-specific CpG markers whose levels of methylation may be highly indicative of known transcriptional markers of immune infiltration such as GZMA, PRF1, T cell receptor genes, PDCD1, and CTLA4. This has been accomplished by integrating genome-wide transcriptional expression a...
Source: Advances in Cancer Research - Category: Cancer & Oncology Authors: Tags: Adv Cancer Res Source Type: research
Accurate segmentation of brain tumors is vital for the gross tumor volume (GTV) definition in radiotherapy. Functional MR images like apparent diffusion constant (ADC) and fractional anisotropy (FA) images can...
Source: BMC Medical Imaging - Category: Radiology Authors: Tags: Research article Source Type: research
Chow Peter D. Chang Radiographic assessment with magnetic resonance imaging (MRI) is widely used to characterize gliomas, which represent 80% of all primary malignant brain tumors. Unfortunately, glioma biology is marked by heterogeneous angiogenesis, cellular proliferation, cellular invasion, and apoptosis. This translates into varying degrees of enhancement, edema, and necrosis, making reliable imaging assessment challenging. Deep learning, a subset of machine learning artificial intelligence, has gained traction as a method, which has seen effective employment in solving image-based problems, including those in me...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Conclusion: SNHG5 gene was high-expressed in glioma, knockdown of SNHG5 inhibits malignant cellular phenotypes of glioma via Wnt/CTNNB1 signaling pathway.
Source: Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Research Paper Source Type: research
Authors: Natsume A, Hirano M, Ranjit M, Aoki K, Wakabayashi T Abstract Glioblastoma (GBM), the most common primary brain tumor, is the most aggressive human cancers, with a median survival rate of only 14.6 months. Temozolomide (TMZ) is the frontline chemotherapeutic drug in GBM. Drug resistance is the predominant obstacle in TMZ therapy. Drug resistance occurs via multiple pathways such as DNA mismatch repair and base excision repair systems, by which glioma cells acquire chemoresistance to some extent (5% and 95%, respectively). Histone3 Lysin27 residue-acetylation (H3K27ac) status regulates cis-regulatory elemen...
Source: Neurologia Medico-Chirurgica - Category: Neurosurgery Tags: Neurol Med Chir (Tokyo) Source Type: research
Authors: Ahmadi-Zeidabadi M, Akbarnejad Z, Esmaeeli M, Masoumi-Ardakani Y, Mohammadipoor-Ghasemabad L, Eskandary H Abstract Glioblastoma multiforme (GBM) is a highly malignant brain tumor with an extremely dismal prognosis, a median survival is12 months. Temozolomide (TMZ) is an alkylating agent widely used to treat cancer, resistance to this drug is often found. One unexplored possibility for overcoming this resistance is a treatment based on concomitant exposure to electromagnetic fields (EMF) and TMZ. Indeed, many evidences show that EMF affects cancer cells and drug performance. Therefore, the present study was...
Source: Electromagnetic Biology and Medicine - Category: Physics Tags: Electromagn Biol Med Source Type: research
Glioma is the most common and lethal type of malignant brain tumor. Accumulating evidence has highlighted that RNA binding protein APOBEC1 complementation factor (A1CF) is involved in various cellular processe...
Source: Journal of Experimental and Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Research Source Type: research
In this study, we engineered novel nanoconjugates composed of Ag-In-S/ZnS quantum dots directly stabilized by chitosan polysaccharide ligand in aqueous medium and biofunctionalized with monoclonal antibody against vascular endothelial growth factor (VEGF) receptors. These nano-immunoconjugates demonstrated bi-functional capabilities combining fluorescent emission for bioimaging and killing activity towards brain cancer cells with very promising perspectives in nanotheranostic applications.Graphical abstract
Source: Materials Letters - Category: Materials Science Source Type: research
Authors: Ji QK, Ma JW, Liu RH, Li XS, Shen FZ, Huang LY, Hui L, Ma YJ, Jin BZ Abstract Cell division cycle associated 7 like (CDCA7L) belongs to the JPO protein family, recently identified as a target gene of c‑Myc and is frequently dysregulated in multiple cancers. However, to the best of our knowledge, no studies to date have been carried out to investigate the functions of CDCA7L in glioma. Thus, in this study, the expression level of CDCA7L and its association with the prognosis in glioma were detected through the TCGA database. The mRNA expression levels of CDCA7L in glioblastoma (GBM) tissues and normal bra...
Source: Molecular Medicine Reports - Category: Molecular Biology Tags: Mol Med Rep Source Type: research
In conclusion, it was demonstrated that PTPN1 is upregulated in glioma tissue and the overexpression of PTPN1 predicted the poor prognosis of patients with glioma. PTPN1 promotes the progression of glioma by activating the MAPK/ERK and PI3K/AKT pathways. PMID: 31173266 [PubMed - as supplied by publisher]
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
More News: Brain | Brain Cancers | Brain Tumor | Cancer | Cancer & Oncology | Food and Drug Administration (FDA) | Glioma | Neurology | Study